Lumanity Executive and Leadership Team

Andrew Dreyfus, the President & Chief Executive Officer at Lumanity, directs the overarching corporate strategy and operational execution. Dreyfus guides Lumanity's mission to accelerate and optimize access to medical advances by applying incisive thinking and decisive action to complex market challenges. This leadership role involves translating Lumanity's deep experience in medical, commercial, and regulatory affairs into actionable insights that power successful commercialization. By ensuring alignment across all business units, Andrew Dreyfus drives the transformation of data into real-world evidence, empowering patients, providers, payers, and regulators to take timely action. The focus remains on turning aspiration into reality, delivering successful development strategies, commercial brand launches, and product campaigns that position Lumanity's clients for sustainable success in the global market.

Rebecca Hyde, the Chief Operating Officer and Global Practice Lead, Value Access and Outcomes at Lumanity, oversees global operational efficiency and the strategic direction of value access and outcomes services. Hyde directs the integration of Lumanity's deep expertise in medical, commercial, and regulatory affairs to generate real-world evidence that demonstrates product value. This leadership position involves ensuring that data and information are transformed into compelling insights that support successful commercialization and empower stakeholders. Rebecca Hyde drives the development of strategies that enable patients, providers, payers, and regulators to take decisive action, particularly in securing market access at a price reflective of product value. The operational scope includes managing Lumanity's global presence across North America, the United Kingdom, Europe, and Asia, ensuring consistent delivery of transformative outcomes for clients worldwide.

Christopher Evans, the President Patient-Centered Outcomes at Lumanity, leads the strategic development and execution of initiatives focused on patient-centered outcomes. Evans directs the generation of evidence that demonstrates the value of medical advances from the patient's perspective, ensuring Lumanity's work directly empowers patients and providers. This role involves translating complex scientific data into compelling narratives that resonate with global stakeholders, highlighting the real-world impact of pharmaceutical and biotech products. Christopher Evans ensures that Lumanity's deep experience in medical and regulatory affairs is leveraged to create insights that support timely and decisive action, particularly in demonstrating product value and enabling successful commercialization. The focus is on transforming data into evidence that supports patient access and positions products for sustainable market success.

Stephen Weisman, the Global President at Lumanity, drives the strategic vision and operational oversight for Lumanity's global market presence and client engagements. Weisman directs the company's efforts to identify and generate the evidence needed to demonstrate product value, ensuring that Lumanity's 1,200+ experts effectively support top pharmaceutical and biotech companies. This leadership position involves translating complex science and data into compelling product narratives relevant to stakeholders worldwide, facilitating sustainable market success. Stephen Weisman ensures that Lumanity's incisive thinking and decisive action cut through complex situations, delivering transformative outcomes that accelerate and optimize access to medical advances. The scope of this role encompasses work conducted in over 50 countries, underscoring Lumanity's commitment to turning aspiration into reality across diverse global markets.

Juliet Munakata, the Global President, HEOR at Lumanity, leads the Health Economics and Outcomes Research (HEOR) practice globally, focusing on demonstrating the value of medical advances. Munakata directs the generation of real-world evidence that quantifies the economic and clinical impact of pharmaceutical and biotech products, empowering payers and regulators to make informed decisions. This role involves translating complex scientific data into compelling value propositions that support successful commercialization and market access. Juliet Munakata ensures that Lumanity's deep expertise in medical and regulatory affairs is applied to create insights that drive decisive action, enabling products to reach patients at a price reflective of their demonstrated value. The strategic imperative is to position products for sustainable success by providing robust evidence that supports market acceptance and patient access.

John Howley, the President, Communications (US) at Lumanity, directs the strategic development and execution of communication initiatives within the United States market. Howley leverages Lumanity's deep experience in commercial affairs to craft compelling product narratives that resonate with diverse stakeholders, including patients, providers, and payers. This leadership role focuses on translating scientific and data-driven insights into clear, impactful communications that support successful commercialization and market access. John Howley ensures that Lumanity's work empowers stakeholders to take timely and decisive action by providing them with the evidence and messaging needed to understand product value. The objective is to position products for sustainable success by building strong brand narratives and facilitating effective engagement across the US healthcare landscape.

Robert Budreau, the President & Producer at Lumanity, oversees the strategic direction and production of key initiatives that translate scientific and data-driven insights into tangible outcomes. Budreau directs the transformation of complex information into compelling narratives and evidence that support the commercialization of medical advances. This leadership role involves ensuring that Lumanity's deep experience in commercial and regulatory affairs is effectively applied to produce impactful strategies for clients. Robert Budreau focuses on turning aspiration into reality by enabling the successful development, launch, and campaign execution of products, ensuring they reach patients at a price reflective of their demonstrated value. The production aspect ensures that Lumanity's transformative outcomes are delivered with precision and effectiveness across global markets.

Marissa Poli, the President at Lumanity, drives strategic initiatives and operational excellence across key business functions. Poli directs the application of incisive thinking and decisive action to cut through complex situations, delivering transformative outcomes that accelerate and optimize access to medical advances. This leadership role involves leveraging Lumanity's deep experience in medical, commercial, and regulatory affairs to transform data into real-world insights and evidence. Marissa Poli ensures that Lumanity empowers patients, providers, payers, and regulators to take timely and decisive action, supporting successful commercialization and sustainable market success for clients. The focus remains on turning aspiration into reality, enabling successful development strategies, commercial brand launches, and product campaigns.